Arcadia Biosciences annual operating margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arcadia Biosciences's operating margin was −51.46% for fiscal 2025.
View full Arcadia Biosciences company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −51.46% | +20.85 pp |
| 2024 | 2024-12-31 | −72.31% | +64.69 pp |
| 2023 | 2023-12-31 | −137.00% | +51.82 pp |
| 2022 | 2022-12-31 | −188.82% | +335.16 pp |
| 2021 | 2021-12-31 | −523.98% | −364.93 pp |
| 2020 | 2020-12-31 | −159.05% | +1498.86 pp |
| 2019 | 2019-12-31 | −1,657.91% | −505.59 pp |
| 2018 | 2018-12-31 | −1,152.32% | −796.76 pp |
| 2017 | 2017-12-31 | −355.56% | +228.50 pp |
| 2016 | 2016-12-31 | −584.07% | −296.61 pp |
| 2015 | 2015-12-31 | −287.46% | −70.43 pp |
| 2014 | 2014-12-31 | −217.03% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −34.37% | +0.06 pp |
| Q1 2026 | 2026-03-31 | −70.82% | −114.98 pp |
| Q4 2025 | 2025-12-31 | −152.83% | +34.82 pp |
| Q3 2025 | 2025-09-30 | −88.48% | +26.03 pp |
| Q2 2025 | 2025-06-30 | −34.43% | −186.04 pp |
| Q1 2025 | 2025-03-31 | 44.17% | +205.06 pp |
| Q4 2024 | 2024-12-31 | −187.65% | −285.90 pp |
| Q3 2024 | 2024-09-30 | −114.51% | −6.88 pp |
| Q2 2024 | 2024-06-30 | 151.61% | +263.71 pp |
| Q1 2024 | 2024-03-31 | −160.89% | +152.99 pp |
| Q4 2023 | 2023-12-31 | 98.25% | +352.45 pp |
| Q3 2023 | 2023-09-30 | −107.63% | −9.57 pp |
| Q2 2023 | 2023-06-30 | −112.10% | +31.47 pp |
| Q1 2023 | 2023-03-31 | −313.88% | +322.00 pp |
| Q3 2022 | 2022-09-30 | −254.20% | +112.50 pp |
| Q2 2022 | 2022-06-30 | −98.06% | +448.71 pp |
| Q1 2022 | 2022-03-31 | −143.57% | +499.67 pp |
| Q4 2021 | 2021-12-31 | −635.88% | −740.64 pp |
| Q3 2021 | 2021-09-30 | −366.71% | +2047.62 pp |
| Q2 2021 | 2021-06-30 | −546.76% | +1900.21 pp |
| Q1 2021 | 2021-03-31 | −643.24% | +1230.55 pp |
| Q4 2020 | 2020-12-31 | 104.75% | +1063.41 pp |
| Q3 2020 | 2020-09-30 | −2,414.33% | −834.48 pp |
| Q2 2020 | 2020-06-30 | −2,446.98% | +7.21 pp |
| Q1 2020 | 2020-03-31 | −1,873.79% | +795.83 pp |
| Q4 2019 | 2019-12-31 | −958.65% | +21.98 pp |
| Q3 2019 | 2019-09-30 | −1,579.85% | −472.01 pp |
| Q2 2019 | 2019-06-30 | −2,454.19% | −1404.19 pp |
| Q1 2019 | 2019-03-31 | −2,669.62% | −875.70 pp |
| Q4 2018 | 2018-12-31 | −980.63% | −770.55 pp |
| Q3 2018 | 2018-09-30 | −1,107.84% | −494.09 pp |
| Q2 2018 | 2018-06-30 | −1,050.00% | −672.91 pp |
| Q1 2018 | 2018-03-31 | −1,793.93% | −1404.63 pp |
| Q4 2017 | 2017-12-31 | −210.08% | +803.06 pp |
| Q3 2017 | 2017-09-30 | −613.75% | −248.45 pp |
| Q2 2017 | 2017-06-30 | −377.09% | +217.77 pp |
| Q1 2017 | 2017-03-31 | −389.29% | +189.70 pp |
| Q4 2016 | 2016-12-31 | −1,013.15% | −710.77 pp |
| Q3 2016 | 2016-09-30 | −365.30% | −132.99 pp |
| Q2 2016 | 2016-06-30 | −594.87% | −346.83 pp |
| Q1 2016 | 2016-03-31 | −578.99% | −123.65 pp |
| Q4 2015 | 2015-12-31 | −302.38% | −244.16 pp |
| Q3 2015 | 2015-09-30 | −232.31% | +163.36 pp |
| Q2 2015 | 2015-06-30 | −248.04% | +135.02 pp |
| Q1 2015 | 2015-03-31 | −455.34% | −267.83 pp |
| Q4 2014 | 2014-12-31 | −58.22% | — |
| Q3 2014 | 2014-09-30 | −395.67% | — |
| Q2 2014 | 2014-06-30 | −383.07% | — |
| Q1 2014 | 2014-03-31 | −187.51% | — |
Over the last five reported fiscal years, Arcadia Biosciences's operating margin increased from −159.05% to −51.46%, a change of +107.59 percentage points. The latest reported quarter, Q2 2026, shows −34.37%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcadia Biosciences filings at SEC.gov ↗